Napo EU, a subsidiary being established by Jaguar Health in Italy has chosen the AIM Italy to list, it was revealed in a webcast organized by the company and a sponsor of the SPAC.
The sponsor of the proposed Post Pandemic Recovery special purpose acquisition company said that a group of multinational institutional investors had already sought an interest of up to 70% of the proposed offering, adding that it is likely to accept funds for the listed SPAC from next week.
Through Napo EU, the company is seeking to obtain conditional marketing authorization in Europe for crofelemer for the indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea in the "long-hauler" COVID-19 recovery patient population.
Jaguar Health announced in November that it was in preliminary discussions with Swiss Growth Forum, a sponsor of a European SPAC for a potential merger of a yet-to-be-established European subsidiary.
https://seekingalpha.com/news/...diary-to-go-public-in-italy-via-spac
|
